Biopharma & Life Sciences
Beam Therapeutics Executive Compensation (FY25)
BEAM · Executive and director compensation, fiscal 2025 only
Data as of September 7, 2026Latest filing (8-K): June 8, 2026
171 figures on this page: 166 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Beam Therapeutics' chief executive and what were they paid?
John Evans was paid $5,818,525 in total compensation as Chief Executive Officer for fiscal 2025.
What was Beam Therapeutics' say-on-pay result?
The say-on-pay proposal drew 98.6% of votes cast for or against in favor at the meeting held June 3, 2026 for fiscal 2025.
Which companies are in Beam Therapeutics' peer group?
Companies named in the disclosed peer group include Agios Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Arcellx, Inc., Arrowhead Pharmaceuticals, Inc. and Blueprint Medicines Corporation, among others.
What is Beam Therapeutics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 22:1, against median employee compensation of $264,185.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Evans Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Giuseppe Ciaramella President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Amy Simon Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Christine Bellon Chief Legal Officer and Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Sravan Emany Chief Financial Officer | ◇ | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Amy Simon | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Amy Simon | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Amy Simon | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Christine Bellon | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Christine Bellon | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Giuseppe Ciaramella | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Giuseppe Ciaramella | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| John Evans | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John Evans | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Giuseppe Ciaramella | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| John Evans | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Christine Bellon | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Sravan Emany | RSU | ◇ | ◇ | — | — |
| Amy Simon | RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Mark Fishman, M.D Lead independent director | ◇ | — | ◇ | — | — | — | ◇ |
Carole Ho, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Graham Cooper | ◇ | — | ◇ | — | — | — | ◇ |
John Maraganore, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Kathleen Walsh | ◇ | — | ◇ | — | — | — | ◇ |
Christi Shaw | ◇ | — | ◇ | — | — | — | ◇ |
Chirfi Guindo | ◇ | — | ◇ | — | — | — | ◇ |
John Evans served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Agios Pharmaceuticals, Inc. AGIO
- Apellis Pharmaceuticals, Inc. APLS
- Arcellx, Inc. ACLX
- Arrowhead Pharmaceuticals, Inc. ARWR
- Blueprint Medicines Corporation BPMC
- BridgeBio Pharma Inc. BBIO
- CRISPR Therapeutics AG CRSP
- Denali Therapeutics Inc. DNLI
- Editas Medicine, Inc. EDIT
- ImmunityBio, Inc. IBRX
- Intellia Therapeutics, Inc. NTLA
- Iovance Biotherapeutics, Inc. IOVA
- Prime Medicine, Inc. PRME
- Rocket Pharmaceuticals, Inc. RCKT
- Sana Biotechnology, Inc. SANA
- Verve Therapeutics, Inc. VERV
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 3, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 4, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 5, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 6, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 8, 2022 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Beam Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Beam Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
171 figures on this page: 166 cited to the filing that reported them, 5 calculated from figures it prints.
166 cited to the filing
5 calculated from the filing
Documents cited
- 0001193125-26-261693Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-161512Director Compensation · Grants of Plan-Based Awards · Non-Employee Director Compensation Policy · Outstanding Awards at Fiscal Year-End · and 1 more section
- 0000950170-25-083043Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-24-071345Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-23-027026Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-22-011501Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Beam Therapeutics executive compensation, FY2025.” https://intel.velarion.ai/comp/BEAM (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Beam Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Beam Therapeutics discloses
The companies named in BEAM's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}